This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
by Zacks Equity Research
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
by Zacks Equity Research
Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug
by Zacks Equity Research
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
by Zacks Equity Research
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Company News for Jul 19, 2022
by Zacks Equity Research
Companies in The News Are: SYF,DAL,BA,SGEN,MRK,SBUX
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study
by Zacks Equity Research
Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.
Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
by Zacks Equity Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ
by Zacks Equity Research
Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.
The Zacks Analyst Blog Highlights American Electric Power, Aspen Technology, Dollar Tree, Seagen and T-Mobile US.
by Zacks Equity Research
American Electric Power, Aspen Technology, Dollar Tree, Seagen and T-Mobile US. are part of Zacks top Analyst Blog
Top 5 Nasdaq Stocks Flying High Amid Index's Bloodbath in 1H
by Nalak Das
We have narrowed our search to five Nasdaq Composite listed stocks that have witnessed a double-digit rally year to date. These are: AEP, AZPN, SGEN, DLTR and TMUS.
Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Seagen (SGEN) is riding on the strong uptake of its marketed drugs that are approved for different cancer indications. Further label expansion of these drugs should boost the top line.
The Zacks Analyst Blog Highlights Visa, JPMorgan Chase, Verizon Communications, Wells Fargo, and Seagen
by Zacks Equity Research
Visa, JPMorgan Chase, Verizon Communications, Wells Fargo, and Seagen are part of Zacks top Analyst Blog.
Top Analyst Reports for Visa, JPMorgan & Verizon
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), JPMorgan Chase & Co. (JPM), and Verizon Communications Inc. (VZ).
Company News for Jun 27, 2022
by Zacks Equity Research
Companies in The News Are: KMX,BZ,FDX,SGEN,MRK
Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck
by Zacks Equity Research
Shares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.
Seattle Genetics (SGEN) Moves 12.7% Higher: Will This Strength Last?
by Zacks Equity Research
Seattle Genetics (SGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Axsome (AXSM) Down 30.3% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.